

TITAN PHARMACEUTICALS INC

Form 8-K

August 02, 2017

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): August 1, 2017

Titan Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware                                      001-13341                                      94-3171940  
(State or Other Jurisdiction of      (Commission File Number) (IRS Employer Identification No.)  
Incorporation)

400 Oyster Point Blvd., Suite 505, South San Francisco, CA 94080  
(Address of Principal Executive Offices)                                      (Zip Code)

Registrant's telephone number, including area code: 650-244-4990

Edgar Filing: TITAN PHARMACEUTICALS INC - Form 8-K

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12(b))

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 5.07. Submission of Matters to a Vote of Security Holders.**

On August 1, 2017, Titan Pharmaceuticals, Inc. (the “Company”) held its annual meeting of stockholders (the “Annual Meeting”). Summarized below are the results of the matters voted on at the Annual Meeting:

1. Election of Directors

Stockholders elected all of the Company’s nominees for director for one-year terms expiring on the next annual meeting of stockholders. The voting results were as follows:

	FOR	WITHHOLD	BROKER NON-VOTE
Marc Rubin	4,659,330	1,122,080	10,399,126
Sunil Bhonsle	4,578,414	1,202,996	10,399,126
Joseph A. Akers	4,853,818	927,592	10,399,126
Rajinder Kumar	4,811,295	970,115	10,399,126
M. David MacFarlane	4,840,307	941,103	10,399,126
James R. McNab, Jr.	4,571,681	1,209,729	10,399,126
Scott A. Smith	4,855,492	925,918	10,399,126

2. Ratification of Auditors

Stockholders ratified the appointment of OUM & Co. LLP to serve as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2017. The voting results were as follows:

FOR	AGAINST	ABSTAIN
<u>14,919,041</u>	<u>755,406</u>	<u>506,089</u>

3. Non-binding Advisory Vote on Executive Compensation

Edgar Filing: TITAN PHARMACEUTICALS INC - Form 8-K

Stockholders, on an advisory basis, approved the compensation of the Company's executive officers. The voting results were as follows:

FOR	AGAINST	ABSTAIN	BROKER NON-VOTES
<u>3,199,559</u>	<u>2,459,118</u>	<u>122,733</u>	<u>10,399,126</u>

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: August 1, 2017 TITAN PHARMACEUTICALS, INC.

By: /s/ Sunil Bhonsle  
Name: Sunil Bhonsle  
Title: Chief Executive Officer and President